Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation.
Kazumasa YamamotoShun YamamotoKen KatoPublished in: Expert opinion on drug safety (2024)
Pembrolizumab-containing therapies are tolerable as first- and second-line treatments in patients with advanced ESCC. Although infrequent, immune-related adverse events may occur in patients on pembrolizumab-containing therapies. These events are potentially fatal and require treatment with steroids or immunosuppressive drugs. Regular physical and laboratory examinations, including measurement of hormone levels, are needed during and after pembrolizumab-containing therapies in clinical practice.
Keyphrases
- squamous cell carcinoma
- advanced non small cell lung cancer
- locally advanced
- clinical practice
- end stage renal disease
- ejection fraction
- newly diagnosed
- small cell lung cancer
- neoadjuvant chemotherapy
- physical activity
- prognostic factors
- mental health
- epidermal growth factor receptor
- radiation therapy
- emergency department
- lymph node metastasis
- patient reported outcomes
- lymph node
- adverse drug
- open label